| Literature DB >> 31095840 |
Cristina Di Carluccio1, Enrique Crisman2, Yoshiyuki Manabe3,4, Rosa Ester Forgione1, Alessandra Lacetera2, Jussara Amato5, Bruno Pagano5, Antonio Randazzo5, Angela Zampella5, Rosa Lanzetta1, Koichi Fukase3,4, Antonio Molinaro1,3, Paul R Crocker6, Sonsoles Martín-Santamaría2, Roberta Marchetti1, Alba Silipo1.
Abstract
CD22 (Siglec-2) is a B-cell surface inhibitory protein capable of selectively recognising sialylated glycans, thus dampening autoimmune responses against self-antigens. Here we have characterised the dynamic recognition of complex-type N-glycans by human CD22 by means of orthogonal approaches including NMR spectroscopy, computational methods and biophysical assays. We provide new molecular insights into the binding mode of sialoglycans in complex with h-CD22, highlighting the role of the sialic acid galactose moieties in the recognition process, elucidating the conformational behaviour of complex-type N-glycans bound to Siglec-2 and dissecting the formation of CD22 homo-oligomers on the B-cell surface. Our results could enable the development of additional therapeutics capable of modulating the activity of h-CD22 in autoimmune diseases and malignancies derived from B-cells.Entities:
Keywords: N-glycans; NMR spectroscopy; Siglecs; molecular recognition; sialic acids
Mesh:
Substances:
Year: 2019 PMID: 31095840 DOI: 10.1002/cbic.201900295
Source DB: PubMed Journal: Chembiochem ISSN: 1439-4227 Impact factor: 3.164